STAT China: A debut for CanSino Biologics and Cellular BioMed’s controversy
In this edition, Covid-19 vaccine updates, a privatization proposal draws a backlash, and the CEO of a newly formed biotech takes question.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario